- Home
- KYNB vs TELA Comparison
KYNB vs TELA Comparison
Compare KYNB & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KYNB | TELA |
|---|---|---|
| Founded | 1993 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.9M | 36.7M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | KYNB | TELA |
|---|---|---|
| Price | $7.43 | $0.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.31 |
| AVG Volume (30 Days) | 28.9K | ★ 332.9K |
| Earning Date | 03-16-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 53.38 | N/A |
| Revenue | $8,298,000.00 | ★ $77,055,000.00 |
| Revenue This Year | N/A | $18.41 |
| Revenue Next Year | N/A | $15.20 |
| P/E Ratio | $0.15 | ★ N/A |
| Revenue Growth | N/A | ★ 12.24 |
| 52 Week Low | $4.85 | $0.68 |
| 52 Week High | $21.94 | $2.96 |
Technical Indicators
Market Signals| Indicator | KYNB | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 37.55 | 32.34 |
| Support Level | $7.50 | $0.76 |
| Resistance Level | $8.25 | $0.87 |
| Average True Range (ATR) | 0.66 | 0.11 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 10.47 | 20.65 |
Price Performance
Historical ComparisonAbout KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
About TELA TELA Bio Inc.
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.